Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice

Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles

George Mattheolabakis, Ruixue Wang, Basil Rigas, Gerardo Mackenzie

Research output: Contribution to journalArticle

Abstract

Subsequently to the publication of the aobve article, the authors have realized that they overlooked including a 'Competing Interests' section. This should have been included in the paper as follows: 'GM, RW and GGM declare they have no competing interests. BR has an equity position in Medicon Pharmaceuticals, Inc., the company that provided the test agent'. The authors regret that this statement was not included in the paper, and apologize for any inconvenience caused. [the original article was published in the International Journal of Oncology 51: 1035-1044, 2017; DOI: 10.3892/ijo.2017.4103].

Original languageEnglish (US)
Number of pages1
JournalInternational Journal of Oncology
Volume53
Issue number6
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Ethylene Glycol
Pancreatic Neoplasms
Nanoparticles
Publications
Emotions
Milk
Acids
Growth
Pharmaceutical Preparations
corrigendum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{a614a3e12daf4b82b0ad6cc43e7f1972,
title = "Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles",
abstract = "Subsequently to the publication of the aobve article, the authors have realized that they overlooked including a 'Competing Interests' section. This should have been included in the paper as follows: 'GM, RW and GGM declare they have no competing interests. BR has an equity position in Medicon Pharmaceuticals, Inc., the company that provided the test agent'. The authors regret that this statement was not included in the paper, and apologize for any inconvenience caused. [the original article was published in the International Journal of Oncology 51: 1035-1044, 2017; DOI: 10.3892/ijo.2017.4103].",
author = "George Mattheolabakis and Ruixue Wang and Basil Rigas and Gerardo Mackenzie",
year = "2018",
month = "12",
day = "1",
doi = "10.3892/ijo.2018.4584",
language = "English (US)",
volume = "53",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice

T2 - Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles

AU - Mattheolabakis, George

AU - Wang, Ruixue

AU - Rigas, Basil

AU - Mackenzie, Gerardo

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Subsequently to the publication of the aobve article, the authors have realized that they overlooked including a 'Competing Interests' section. This should have been included in the paper as follows: 'GM, RW and GGM declare they have no competing interests. BR has an equity position in Medicon Pharmaceuticals, Inc., the company that provided the test agent'. The authors regret that this statement was not included in the paper, and apologize for any inconvenience caused. [the original article was published in the International Journal of Oncology 51: 1035-1044, 2017; DOI: 10.3892/ijo.2017.4103].

AB - Subsequently to the publication of the aobve article, the authors have realized that they overlooked including a 'Competing Interests' section. This should have been included in the paper as follows: 'GM, RW and GGM declare they have no competing interests. BR has an equity position in Medicon Pharmaceuticals, Inc., the company that provided the test agent'. The authors regret that this statement was not included in the paper, and apologize for any inconvenience caused. [the original article was published in the International Journal of Oncology 51: 1035-1044, 2017; DOI: 10.3892/ijo.2017.4103].

UR - http://www.scopus.com/inward/record.url?scp=85056802095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056802095&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4584

DO - 10.3892/ijo.2018.4584

M3 - Article

VL - 53

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -